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identify techniques for evaluating the results of country-
specific cost-effectiveness ratios derived from such trials.
Participants will learn when it is more appropriate to use
country-specific ratios and when it is more appropriate to
use the more precise pooled (average) ratio for the overall
study to represent these countries’ ratios.
PARTICIPANTS WHO WOULD BENEFIT: Designers,
analysts, and managers of multinational trials as well as
consumers of the results of such trials.
As economic studies are more frequently being per-
formed in multinational trials, the question is raised
whether the results of economic evaluations in these trials
can inform decision-makers in the individual countries in
which the trial was performed? We propose the use of re-
sampling procedures to estimate point estimates and vari-
ances for the angles representing country-specific cost-ef-
fectiveness ratios. These point estimates and variances
are then used to assess the homogeneity of the resulting
ratios. These methods are illustrated using data from two
multinational trials. In one, even though treatment pat-
terns and outcomes differed among the countries, the
treatment effect on costs, effects, and the cost-effective-
ness ratio were homogeneous. In the second, we found
evidence of heterogeneity in these effects. Data currently
being collected in multinational trials can help us under-
stand if the pooled ratio from the trial is representative of
the ratios for the individual countries enrolled in the trial.
WMD3
NEW METHODS OF DATA COLLECTION IN THE 
COMMUNITY-BASED PHYSICIAN SETTING: 
PROCESS AND TECHNOLOGY
Jardina P, Irwin C
Physicians Data Corporation, Atlanta, GA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to discuss and develop skills in formulating
new methods for clinical data collection in the commu-
nity-based physician setting.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who are interested in moving beyond administrative
data for longitudinal outcomes studies, but who are con-
strained by the complexity, time and effort of traditional
clinical data collection methods would benefit from this
workshop.
Data collection is a critical component of pharmacoeco-
nomic and outcomes studies, and is often a key limiter of
study design and scope. This workshop identifies several
methods of clinical data collection in the community-
based physician setting. This information has broad util-
ity, including support of the conduct of pharmacoeco-
nomics and outcomes research. Because dictation and
transcription are the preferred means of documenting pa-
tient encounters, this workshop focuses on the role of
people, process and technology within that environment.
Will physicians change their behavior to support collec-
tion of data elements needed to conduct studies? What
types of technologies are needed to support discrete data
element capture in a dictation/transcription environment?
What is the evolving role the electronic medical record in
data collection? How are electronic data stores utilized to
cost-effectively validate source data? How can one over-
come the challenges of codifying data elements that are
collected in natural language? What is the role of manual
processes in augmenting automated data collection? The
workshop will present and explore practical strategies for
collecting, managing and reporting clinical information in
the community-based physician environment. Data col-
lected through September 1998 on 5865 coronary artery
disease patients will be presented to demonstrate results
from the techniques presented.
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WORKSHOP OBJECTIVE: The workshop participants
will develop skills to identify limitations in market data,
to design an SP survey that will remedy the limitations in
market data, and to understand analytical methods that
combine both existing market data and stated-preference
survey data.
PARTICIPANTS WHO WOULD BENEFIT: New drug
developers, pharmaceutical marketers, and others in-
volved in the analysis of pharmaceutical market demand.
Market data for existing pharmaceuticals is useful in
many situations. However, it has limitations. For exam-
ple, market data contains only existing drugs’ sales.
Thus, it can not provide information on the demand for a
new pharmaceutical in a therapeutic class. The usefulness
of market data also may be limited by low variation in
variables of interest or highly correlated product charac-
teristics. In this workshop, the presenters will demon-
strate methods for augmenting reality-based market data
with data derived from an appropriately designed stated
preference (SP) survey. SP surveys provide the opportu-
nity to assess preferences for product attributes that do
not currently exist in the market or for which market
data is limited. Participants will learn how to apply SP
methods by interactively developing a simple SP survey.
The presenters will introduce the methods used in devel-
oping and administering an SP survey and will present
methods of linking market and SP data that exploit the
richness of both data sources. Finally, the presenters will
demonstrate the power of linking market and SP data.
The example estimates predicted sales of a novel drug
that will be introduced in a mature market.
